

March 28, 2019

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Norio Hamada, Chairman of the Board and Representative Director, Chief Executive Officer (CEO) (First Section of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Director and General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

**Notice Regarding the Transfer of Marketing Approvals for
11 Ingredients / 28 Products of Generic Drugs for KYOSOMIRAI PHARMA**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, regarding transfer of pharmaceutical marketing approvals (26 ingredients) and sales rights (30 ingredients) from FUJIFILM Pharma Co., Ltd. (Headquarters: Tokyo; Representative Director and President: Susumu Tanahashi) notified on July 27, 2018, completed transfer of marketing approvals for 11 ingredients / 28 products today on March 28, 2019 as below.

Please also be informed that, as a result of this transfer, the transfer of marketing approvals (26 ingredients / 64 products) and sales rights (30 ingredients / 50 products) for pharmaceuticals from FUJIFILM Pharma Co., Ltd. has been completed and KYOSOMIRAI PHARMA CO., LTD. now markets 73 ingredients / 156 products in total.

1. Products whose marketing approvals are transferred

Classes	Product Name	Original Brand Name
Long-acting calcium-channel blocker	Azelnidipine Tablets 8mg / 16mg "FFP"	CALBLOCKTABLETS 8mg / 16mg
Oral sulfonylurea hypoglycemic agent	Glimepiride Tablets 0.5mg / 1mg / 3mg "FFP"	Amaryl Tablets 0.5mg / 1mg / 3mg Tablets
Antiplatelet drug	Clopidogrel Tablets 25mg / 75mg "FFP"	Plavix Tablets 25mg / 75mg
5-HT _{1B/1D} receptor agonist for migraine	Sumatriptan Tablets 50mg "FFP"	IMIGRAN Tablets 50
Therapeutic agent for Alzheimer's disease	Donepezil Hydrochloride Tablets 3mg / 5mg / 10mg "FFP"	Aricept Tablets 3mg / 5mg / 10mg
	Donepezil Hydrochloride OD Tablets 3mg / 5mg / 10mg "FFP"	Aricept D Tablets 3mg / 5mg / 10mg
Selective serotonin reuptake inhibitor	Paroxetine Tablets 5mg / 10mg / 20mg "FFP"	Paxil Tablets 5mg / 10mg / 20mg

Classes	Product Name	Original Brand Name
Insulin-sensitizing agent -Therapeutic agent for type 2 diabetes mellitus -	Pioglitazone Tablets 15mg / 30mg “FFP”	ACTOS Tablets 15 / 30
	Pioglitazone OD Tablets 15mg / 30mg “FFP”	ACTOS OD Tablets 15 / 30
Dopamine agonist for Parkinson's disease / restless legs syndrome	Pramipexole Hydrochloride Tablets 0.125mg / 0.5mg “FFP”	BI-Sifrol Tablets 0.125mg / 0.5mg
Therapeutic agent for osteoporosis	Risedronate Na Tablets 2.5mg / 17.5mg “FFP”	Actonel Tab. 2.5mg / 17.5mg BENET Tablets 2.5mg / 17.5mg
Aromatase inhibitor / therapeutic agent for post-menopausal breast cancer	Letrozole Tablets 2.5mg “FFP”	Femara Tablets 2.5mg
Extended-release selective histamine H1 antagonist / therapeutic agent for allergic disease	Loratadine Tablets 10mg “FFP”	Claritin Tablets 10mg
	Loratadine OD Tablets 10mg “FFP”	Claritin Reditabs 10mg